ストックスクリーナーアプリを入手
0.4318
1.53%
-0.0067
アフターアワーズ：
.43
-0.0018
-0.42%
前日終値:
$0.4385
開ける：
$0.435
24時間の取引高:
712.45K
Relative Volume:
0.14
時価総額：
$31.74M
収益：
-
当期純損益:
$-51.50M
株価収益率:
-0.108
EPS:
-4
ネットキャッシュフロー:
$-47.10M
1週間 パフォーマンス:
-0.35%
1か月 パフォーマンス:
+10.72%
6か月 パフォーマンス:
-53.82%
1年 パフォーマンス:
-71.21%
1日の値動き範囲:
$0.42
$0.4544
1週間の範囲:
$0.404
$0.4544
52週間の値動き範囲:
$0.3801
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
名前
Outlook Therapeutics Inc
セクター
電話
(609) 619-3990
住所
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.4318 | 32.23M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-02 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-02-15 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-27 | アップグレード | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-08-30 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | ダウングレード | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-07-13 | 開始されました | CapitalOne | Overweight |
| 2023-04-03 | 開始されました | Guggenheim | Buy |
| 2023-02-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-10-31 | 開始されました | BTIG Research | Buy |
| 2022-09-13 | 開始されました | Chardan Capital Markets | Buy |
| 2019-09-11 | 開始されました | Ladenburg Thalmann | Buy |
| 2019-05-16 | 開始されました | Oppenheimer | Outperform |
| 2019-04-22 | 開始されました | Ascendiant Capital Markets | Buy |
すべてを表示
Outlook Therapeutics Inc (OTLK) 最新ニュース
Outlook Therapeutics Updates FDA Path For ONS-5010 Following Type A Meeting - Nasdaq
FDA meeting prompts new ONS-5010 update, Outlook Therapeutics outlines - Traders Union
Outlook Therapeutics (OTLK) Advances Towards FDA Approval for ONS-5010 - GuruFocus
Outlook Therapeutics advances FDA dialogue on ONS-5010 approval - TipRanks
Outlook Therapeutics discusses FDA meeting on bevacizumab drug - Investing.com
Outlook Therapeutics Offers Update After FDA Meeting About ONS-5010/LYTENAVA - marketscreener.com
Outlook Therapeutics provides update following Type A meeting with FDA - marketscreener.com
Outlook Therapeutics Provides Update Following Type A Meeting With FDA - TradingView
Outlook Therapeutics (Nasdaq: OTLK) details FDA Type A meeting on ONS-5010 - Stock Titan
First bevacizumab eye drug? Outlook, FDA discuss path for ONS-5010 - Stock Titan
Can Outlook Therapeutics Inc reach all time highs this yearJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Risk On: Will Outlook Therapeutics Inc benefit from AI trendsJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
OTLK Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Buyback Watch: Is Old Point Financial Corporation a good ESG investment2025 EndofYear Setup & Daily Profit Focused Screening - baoquankhu1.vn
OTLKW News Today: Stay Updated with the Latest Outlook Therapeutics, Inc.Se News in Real Time - Meyka
Aug Macro: Will Outlook Therapeutics Inc benefit from government policyMarket Sentiment Summary & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Key facts: Outlook Therapeutics Faces Nasdaq Compliance Deadline; Signs Deal with Mediconsult AG - TradingView
Outlook Therapeutics Signs Exclusive Distribution Deal With Mediconsult for Lytenava - marketscreener.com
Outlook Therapeutics (OTLK) Secures Swiss Distribution Deal for Lytenava - GuruFocus
Outlook Therapeutics, Inc. accelerates its European market expansion plan through partnerships, with its innovative drug Lytenava expected to officially enter the Swiss market in 2027. - Bitget
Can Outlook Break The Cycle With Fresh FDA Meeting On Ophthalmic Bevacizumab? - Citeline News & Insights
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland - The Manila Times
Outlook Therapeutics, Inc. accelerates its European market expansion plans through partnerships, with its innovative drug Lytenava expected to officially enter the Swiss market in 2027. - Bitget
Outlook Therapeutics Reports Q1 Fiscal Year 2026 Financial Results - VisionMonday.com
Outlook Therapeutics (OTLK) Maintains Neutral Rating According t - GuruFocus
Outlook Therapeutics Faces Nasdaq Minimum Bid Price Noncompliance - TipRanks
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA (bevacizumab gamma) in Switzerland - Bitget
Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Key facts: Outlook Therapeutics reports $1.2M loss; LYTENAVA launched in Europe - TradingView
OTLK: Analyst Maintains Neutral Rating and Price Target | OTLK S - GuruFocus
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - The Globe and Mail
Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView
OTLK: Net loss of $23.1M, negative revenue, and liquidity risks amid delayed US approval for LYTENAVA - TradingView
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025 - marketscreener.com
OTLK: European sales of LYTENAVA doubled, but US approval for ONS-5010 remains uncertain - TradingView
Outlook Therapeutics swings to Q1 net loss - TradingView
Outlook Therapeutics Advances LYTENAVA™ Expansion in Europe with Launch Scheduled for Austria and Regulatory Update for ONS-5010 in the U.S. - Quiver Quantitative
Outlook Therapeutics Earnings Report: Q1 Overview - Benzinga
Published on: 2026-02-16 11:51:16 - mfd.ru
Sell Signal: Can Outlook Therapeutics Inc. stock maintain growth trajectoryDay Trade & Free Accurate Trade Setup Notifications - mfd.ru
OTLK Stock Price, Forecast & Analysis | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA - The Globe and Mail
SPHERA FUNDS MANAGEMENT LTD. Acquires Significant Stake in Outlo - GuruFocus
Key facts: Outlook Therapeutics Seeks FDA Meeting on ONS-5010 Issues - TradingView
IPO Launch: What drives Renasant Corporations stock priceQuarterly Earnings Summary & Daily Growth Stock Tips - baoquankhu1.vn
Outlook Therapeutics submits Type A meeting request to FDA following Complete Response Letter - marketscreener.com
Outlook Therapeutics Submit Type A Meeting Request To FDA Following CRL - Nasdaq
Outlook Therapeutics Submits Type A Meeting Request To FDA Following Complete Response Letter - TradingView
Outlook Therapeutics (OTLK) Faces FDA Request for Additional Evi - GuruFocus
Outlook Therapeutics seeks FDA meeting after response letter - Traders Union
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter - GlobeNewswire
Outlook Therapeutics Inc (OTLK) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):